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Abstract
Background: There is an urgent need to substitute the highly toxic compounds still in use for treatment of the encephalitic
stage of human African trypanosomiasis (HAT). We here assessed the treatment with the doublet cordycepin and the
deaminase inhibitor deoxycoformycin for this stage of infection with Trypanosoma brucei (T.b.).
Methodology/Principal Findings: Cordycepin was selected as the most efficient drug from a direct parasite viability
screening of a compound library of nucleoside analogues. The minimal number of doses and concentrations of the drugs
effective for treatment of T.b. brucei infections in mice were determined. Oral, intraperitoneal or subcutaneous
administrations of the compounds were successful for treatment. The doublet was effective for treatment of late stage
experimental infections with human pathogenic T.b. rhodesiense and T.b. gambiense isolates. Late stage infection treatment
diminished the levels of inflammatory cytokines in brains of infected mice. Incubation with cordycepin resulted in
programmed cell death followed by secondary necrosis of the parasites. T.b. brucei strains developed resistance to
cordycepin after culture with increasing concentrations of the compound. However, cordycepin-resistant parasites showed
diminished virulence and were not cross-resistant to other drugs used for treatment of HAT, i.e. pentamidine, suramin and
melarsoprol. Although resistant parasites were mutated in the gene coding for P2 nucleoside adenosine transporter, P2
knockout trypanosomes showed no altered resistance to cordycepin, indicating that absence of the P2 transporter is not
sufficient to render the trypanosomes resistant to the drug.
Conclusions/Significance: Altogether, our data strongly support testing of treatment with a combination of cordycepin and
deoxycoformycin as an alternative for treatment of second-stage and/or melarsoprol-resistant HAT.
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Introduction
Human African trypanosomiasis (HAT), also known as sleeping
sickness, is a neglected tropical infectious disease that has re-
emergedinsub-Saharan Africainthelate 1900
ties [1,2]. The disease
is caused by subspecies of the protozoan parasite Trypanosoma brucei
and istransmitted bytheblood-suckingtsetsefly. Followinga hemo-
lymphatic stage with waves of parasitemia, the nervous system is
involved manifested as a leukencephalitis, invariably lethal if left
untreated. Drugs, which are effective at an early stage of the disease,
but poorly penetrate the blood-brain barrier, are ineffective for the
second stage. For treatment of the second encephalitic stage of
HAT, arseniccompounds such as melarsoprol, whichare associated
with severe and even lethal side-effects, are still widely used.
Moreover, there has been an alarming increase in melarsoprol-
refractory sleeping sickness cases [3]. Dl-a-difluoromethylornithine
(DFMO) is used for treating the West African form of HAT, caused
by T.b. gambiense. However, this drug is given by intravenous
injections, is expensive, and is not effective against T.b. rhodesiense
that causesthe East African form of HAT. Since the development of
new drugs for HAT is not likely to occur in the immediate future,
the strategy of testing drugs approved or in clinical use for other
diseases should be pursued in order to identify less toxic or
alternative drugs to cure second stage HAT [4].
In contrast to most mammalian cells, trypanosomes cannot
synthesize purines de novo. Instead they depend on the salvage
pathway of nucleosides from the body fluids of the host [5]. The
inability of trypanosomes to engage in de novo purine synthesis has
been exploited as a therapeutic target. The trypanocidal potential
of cordycepin (39-deoxyadenosine), a metabolite from the fungi
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[6,7]. However, administration of cordycepin did not result in a
complete cure from infection [8], since cordycepin is rapidly
converted to inactive 39-deoxyinosine by adenosine deaminase
(ADA) in vivo [9]. Deoxycoformycin is an ADA inhibitor that can
prevent degradation of cordycepin, and have come into use in
combination with cordycepin for the treatment of certain
malignant tumors in humans, e.g. leukemia and melanoma [10].
Cordycepin is probably taken up by trypanosomes through
transporters. Nucleoside transport systems, P1 and P2, are able to
concentratecordycepininsidethecellsand hasturnedout toplayan
important role in the uptake of trypanocides [11]. Adenosine is
salvaged through a two-step process in T. brucei where its
intracellular cleavage to adenine is followed by phosphoribosylation
to AMP, or by a high affinity adenosine kinase [12,13]. Cordycepin
is also a potent inhibitor of the mammalian poly-A polymerase, and
has been shown to hamper the activity of nucleoside-stimulated
protein kinase activity in Trypanosoma sp. [14].
We have previously shown that intraperitoneal (i.p.) injection of
cordycepin, together with coformycin or deoxycoformycin, can
cure T.b. brucei infections in mice [15]. Treatment was effective, as
recorded by the absence of parasitemia up to three weeks after the
end of the treatment, even when instituted after the trypanosomes
had penetrated into the brain parenchyma. The aim of the present
work was to further improve treatment strategies with nucleosides,
and gain knowledge on the effect of these compounds on the
parasite. We could show that cordycepin is the best candidate drug
selected after screening a library of 2200 nucleoside analogues for
parasite differential toxicity. The minimal inhibitory concentra-
tions of cordycepin and deoxycoformycin and the minimal
number of doses required for effective treatment were then
determined in mice infected with T.b. brucei. Cordycepin and
deoxycoformycin treatment did also cure second stage infection
with human pathogenic T.b. gambiense and T.b. rhodesiense, and oral
administration of the duplet when combined with a proton pump
inhibitor was effective. Cultivation of T.b. brucei with low doses of
cordycepin allowed resistance to cordycepin to develop, but
resistant parasites lost virulence, and no cross-resistance between
cordycepin and melasoprol. suramin and pentamidine was noted.
Importantly treated mice showed diminished levels of pro-
inflammatory cytokines in the brain.
Altogether, our findings encourage the possible use of
cordycepin and deoxycoformycin as an alternative for treatment
of second stage HAT or melasoprol-resistant HAT.
Methods
Reagents
Cordycepin, suramin, pentamidine, omeprazole and EHNA
(erythro-9-(2-hydroxy-3-nonyl)adenine) were all purchased from
Sigma (St Louis, MO). Deoxycoformycin (pentostatin) was a kind
gift of R. McCaffrey (Brigham & Women’s Hospital, Harvard
Medical School, Boston, Massachusetts). Melarsoprol (Arsobal)
was a gift from P. Simarro (WHO/NTD, Geneve, Switzerland).
Unless otherwise indicated, all reagents were diluted in PBS,
fractioned and stored at 220uC until further use.
The library of nucleoside analogs used consisted of compounds
design to be inhibitors of various viral and microbial enzymes and
is property of Medivir AB.
Mice
BALB/c, C57Bl/6 and RAG1
2/2 [16] (backcrossed on a
C57Bl/6 background) male mice, 8–10 weeks old at the beginning
of the experiments, were used. Mice were kept with food and
water ad libitum under specific pathogen-free conditions. All
experiments were conducted following protocols that received
institutional approval and authorization by the Stockholm
Region’s animal protection committee.
Parasites
T.b. brucei (AnTat1.1E), T.b. rhodesiense (STIB 851) and T.b.
gambiense (MBA) were kindly provided by P. Bu ¨scher (Institute of
Tropical Medicine, Antwerp, Belgium). Tbat1 null parasites
constructed by sequential homologous recombination of T.b. brucei
Lister 427 [17], were kindly provided by P. Maser (University of
Bern, Switzerland). Lister 427 parasites were used as controls.
Parasitemia was measured every 2 or 3 day in tail vein blood. Body
weight and morbidity were regularly recorded.
Parasite culture and viability
Bloodstream forms of T.b. brucei, T.b. gambiense and T.b.
rhodesiense freshly isolated from infected C57BL/6 mice (3 days
post infection with 1610
7 parasites/mouse) were separated by
DEAE-cellulose chromatography under sterile conditions [18]. T.
brucei parasites were incubated in D-MEM containing 10% heat-
inactivated calf serum, 28 mM HEPES, 0.14% glucose, 1.5%
NaHCO3, 2 mM L-glutamate, 0.14 mg/ml gentamycin, 0.3 mM
dithiothreitol, 1.4 mM sodium pyruvate, 0.7 mM L-cysteine,
28 mM adenosine, 14 mM guanosine at 37uC.
To measure drug sensitivity, 2.5610
4 parasites were cultured in
96 flat-bottomed well culture plates with serial drug dilutions for
72 h at 37uC. Cultures (100 ml) were incubated for 2 h with 10 mlo f
WST-1 reagent (Roche, Mannheim, Germany). Viability was
measured by the conversion of WST-1 reagent to formazan,
recorded by multiwell scanning spectrophotometer at an excitation
wavelength of 450 nm. A direct correlation between WST-1 reagent
oxidation and parasite numbers was confirmed (data not shown).
Immunohistochemistry
Mice were deeply anesthetized with isoflurane, sacrificed and
brains were dissected and snap frozen. To examine presence of
trypanosomes within and outside the blood vessels in the brain,
Author Summary
There is an urgent need to substitute the highly toxic
arsenic compounds still in use for treatment of the
encephalitic stage of African trypanosomiasis, a disease
caused by infection with Trypanosoma brucei. We exploit-
ed the inability of trypanosomes to engage in de novo
purine synthesis as a therapeutic target. Cordycepin was
selected from a trypanocidal screen of a 2200-compound
library. When administered together with the adenosine
deaminase inhibitor deoxycoformycin, cordycepin cured
mice inoculated with the human pathogenic subspecies T.
brucei rhodesiense or T. brucei gambiense even after
parasites had penetrated into the brain. Successful
treatment was achieved by intraperitoneal, oral or
subcutaneous administration of the compounds. Treat-
ment with the doublet also diminished infection-induced
cerebral inflammation. Cordycepin induced programmed
cell death of the parasites. Although parasites grown in
vitro with low doses of cordycepin gradually developed
resistance, the resistant parasites lost virulence and
showed no cross-resistance to trypanocidal drugs in
clinical use. Our data strongly support testing cordycepin
and deoxycoformycin as an alternative for treatment of
second-stage and/or melarsoprol-resistant HAT.
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VSG (1:5.000; obtained from N. van Meirvenne, Institute of
Tropical Medicine, Antwerp, Belgium) and goat polyclonal anti-
glucose transporter 1 (1:40; GLUT-1, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) as described previously [19].
Biophotonic measurement of parasite dissemination
Stable recombinant Renilla luciferase expressing parasites were
generated as recently described (F Claes, submitted). The use of such
luciferase tagged T. brucei for real time studies of parasite dynamics was
validated in vitro and ex vivo (F. Claes, PLoS NTD in press).
BABLB/c mice were infected i.p. with 2610
3 luciferase tagged T.b.
brucei AnTat1.1. At different days after infection, mice were
anesthetized with 2.3% isoflurane, injected intraperitoneally with
100 mLo fc o e l e n t e r a z i n e( 2mg/ml dissolved in methanol) (Synchem)
diluted with 90 mL PBS pH 7, and light emission in photons/second/
cm
2/steradian (p/sec/cm
2/sr) was recorded in an IVIS Imaging
System 100 (Xenogen LifeSciences) and Living Image 2.20.1 software
(Xenogen) for 180 seconds. Measurements started 3–5 minutes after
substrate injection to allow the spread of the coelenterazine.
Markers for apoptosis
DNA content. Briefly, following a 30 min permeabilization of
trypanosomes in 10 mM phosphate buffer containing 6 mM
digitonin, nuclei were stained with a 10 mg/ml propidium iodide
solution in 10 mM phosphate buffer and kept on ice until
measurement by flow cytometry.
DNA fragmentation. DNA fragmentation was assessed by
using the terminal deoxynucleotidyltransferase-mediated dUTP
nick end labeling method (Roche) as described [20]. Analysis was
performed on a Becton Dickinson FACScan, and data were
acquired on a minimum of 10,000 cells per sample.
Phosphatidylserine exposure. Exposed phosphatidylserine
was detected on the outer membrane of cells using Annexin-V-
Fluor (Roche) following instructions by the manufacturer.
Fluorescence was measured using FACS analysis as described
before [21].
Necrosis. In order to analyze disruption of the plasma
membrane after cordycepin treatment, nuclei were stained with
propidium iodide (5 mg/ml) in the absence of a cell permeant and
analyzed by flow cytometry.
Real time RT-PCR
Gene transcripts of several pro-inflammatory cytokines were
quantified in brains from cordycepin-treated and PBS-treated,
uninfected and infected mice by real time PCR. Total RNA was
extracted from half of the fresh frozen brains, reverse-transcribed,
and the transcripts levels quantified on an ABI Prism 7000
sequence detection system (Applied Biosystems) as described
previously [16]. Ten-fold dilutions of a cDNA sample were
amplified to control amplification efficiency for each primer pair.
Thereafter, the threshold cycle value, Ct (the fractional cycle
number at which the fluorescence reaches a fixed threshold) was
obtained for all cDNA samples. The amount of transcripts of
individual animal samples (n=4 per group) was normalized to
HPRT (DCt). The relative amount of target gene transcripts was
calculated using the 2
2DDCt method as described [22]. These
values were then used to calculate the mean and standard error of
the relative expression of the target gene mRNA in the brain of
uninfected and infected mice.
Parasite DNA amplification
Total DNA was extracted from brains from treated and
untreated mice using a Dneasy tissue kit (Qiagen, Duesseldorf,
Germany). The amount of parasite DNA was quantified by real
time PCR as described above using senso latu T. brucei primers [23].
The concentration of DNA in each sample was measured in a
spectrophotometer. A correlation between parasite numbers and
quantification of parasite DNA by real time PCR was determined.
Candidate genes cloning and sequencing
Total DNA from parental and resistant strains was extracted
using the DNeasy tissue kit (Qiagen). Candidate genes suspected to
be involved in the resistance to cordycepin were PCR amplified
from total DNA using forward and reverse specific primers
designed over the following annotated genes by the T. brucei
genome project (Table S1): Adenosine kinase, Adenine phosphor-
ibosyltransferase (APRT), Hypoxanthine-guanine phosphoribosyl-
transferase (HGPRT), Poly(A) polymerase, Hexose Transporter 1
(HT1), Aminopurine Transporter (AT1 or P2), P1 family of
nucleoside transporters (NT2, NT4, NT6 and NT12). PCR
products were A-tailed and ligated into pGEM T-vector (Promega,
Madison, WI). A set of 6 to 12 positive colonies for each gene was
sequenced using the DYEnamic ET dye terminator kit and a
Megabase sequencer (GE) with m13 forward and reverse primers,
and when needed gene specific internal primers. Sequences were
assembled and analyzed using phred-phrad and consed. Sequence
analysis and comparisons between parental and resistant strains
and genome-annotated versions were performed with ClustalW
(www.ebi.ac.uk) and Blast2seq (www.ncbi.nlm.nih.gov). Single
nucleotide polymorphisms between clones were taken into
account.
Results
Screening of a nucleoside compound library
We have previously suggested that cordycepin could be used for
treatment of second stage African trypanosomiasis. Whether other
nucleoside analogues could have a more selective toxic effect on
T.b. brucei was first studied. For this purpose we screened a library
of 2200 drug-like nucleosides compounds for toxicity against T.b.
brucei AnTat1.1. The screening revealed 14 hits showing toxicity
for T.b. brucei at less than 1 mM concentration. Ten of these
compounds were found to also be toxic for mammalian cells at
these concentrations. One of the remaining compounds was
identified as cordycepin. A second one was tubercidin, a
nucleoside previously shown to inhibit the respiratory chain in
T.b. brucei, but that induced adaptation of parasites to a glucose-
independent metabolism [24]. The two other compounds were
diamines, N9trityl-1,2-diaminoethane hydrobromide and N-trityl-
1,3-siaminopropane acetate, included in the library as intermedi-
ates used in the chemical synthesis of nucleoside analogues.
Subsequently, the trypanocidal activity of cordycepin was
compared with that of adenosine deaminase resistant nucleoside
analogues. Such nucleosides could potentially act as stand-alone
drugs in treatment of T.b. brucei infections. Three out of 22 tested
compounds showed at least 3 log higher toxicity for T.b. brucei as
compared to mammalian HL-cells (Figure 1A–B and data not
shown). One is 2-fluorodeoxyadenosine and the other are two
synthetic cordycepin derivatives: 6-N-(phenylthio)-methyl-cordy-
cepin (cordycepin 110) and 6-N-(4-N-acethylbenzylthio)-methyl-
cordycepin (cordycepin 116). As expected, deoxycoformycin was
not toxic for T.b. brucei (data not shown).
The two synthetic derivatives of cordycepin were tested in vivo.
Cordycepin 116, but not cordycepin 110, showed anti-trypanoso-
mal effect during the early stage of infection (Figure 1C). However,
no curative effect was observed when 2 mg/kg/d cordycepin 116
was inoculated during 10 days in the absence of deoxycoformycin
Nucleoside Treatment of African Trypanosomiasis
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Thus, we decided to restrict our further evaluation of the effects of
treatment to cordycepin during infection with T. brucei on the host
and the parasite.
Determination of minimal effective cordycepin
concentrations
Experiments were then performed to confirm, using more
extended protocols, the curative effect of cordycepin and
deoxycoformycin on the second stage murine infection with T.b.
brucei. In order to detect the presence of remnant parasites in the
tissues of treated animals, immunodeficient RAG-1
2/2 mice were
inoculated i.p. with blood or brain tissue homogenates of infected
and treated mice. A double immuno-labelling method using
antibodies against trypanosomes and cerebral endothelial cells was
used to detect parasites in the brain parenchyma. Stained sections
from brain of treated animals (4 per animal) were analyzed.
Parasite DNA in whole blood or brain tissues was measured by
real time PCR.
In a first experiment we showed that none of the C57Bl/6 mice
(n=9) treated i.p. with 2 mg/kg body weigth (kg)/day (d)
cordycepin and 0.2 mg/kg/d deoxycoformycin for 7 consecutive
days, starting at day 20 after infection with 2610
3 T.b. brucei.
displayed parasites at 85 days of infection (65 days after treatment).
No parasites were detected in the blood of cordycepin- and
deoxycoformycin-treated mice. On the contrary, although no
parasites were detected directly after treatment with 20 mg/kg
suramin, the presence of parasites was recorded at least once in the
blood of all suramin-treated mice before sacrifice (65 days after
treatment), although only in a fraction of mice at a given time.
Whereas all RAG1
2/2 mice inoculated with blood or brain
homogenatesfromsuramin-treatedmiceshowedparasitesearlyafter
infection, no parasites were detected in mice inoculated with either
blood or brain homogenates from cordycepin- and deoxycoformy-
cin-treated mice. Parasite DNA could not be amplified and parasite
antigens were not detected in the brain tissues of cordycepin- and
deoxycoformycin-treated mice. Infected and non-treated mice
showed signsof morbidity beforeday32afterinfection. Nomortality
was recorded in the cordycepin-treated group and 1 out of 8
suramin-treated mice died 79 days after infection.
In a second experiment the minimal effective concentration of
cordycepin was determined. For this purpose, we compared the
treatment of mice given different doses of cordycepin and a
constant dose of deoxycoformycin. Mice were inoculated with 2,
1.2 and 0.6 mg/kg/d cordycepin plus 0.2 mg/kg/d deoxycofor-
mycin for 7 days starting at day 20 after infection. Whereas the
trypanocidal effect was evident in all groups of mice (n=9), a dose-
dependent effect was observed, with doses lower than 2 mg/kg/d
Figure 1. Trypanocidal activity of cordycepin and cordycepin derivatives. A, B T.b. brucei or HL cells were incubated in vitro with different
concentrations of the indicated compounds for 48 h. The relative OD values with respect to untreated cells after WST-1 A) or crystal violet staining B)
is shown. The IC50 of cordycepin and derivatives against T. b. brucei AnTat1.1 were cordycepin: 32 nM; cordycepin 110: 26 nM and cordycepin 116:
128 nM. The IC50 for HL cells of the same compounds was in the range of 50–100 mM. C, D Mice were infected i.p. with 2610
3 T.b. brucei. Parasitemia
levels in mice treated with 2 mg/kg/d of the indicated cordycepin derivatives for 2 days starting at the day of infection C) or 20 days after infection D)
were measured. A control infected group was left untreated. The mean parasitemia and the standard error of the mean are depicted.
doi:10.1371/journal.pntd.0000495.g001
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of 9 mice inoculated with 2 mg/kg/d cordycepin showed parasites
before 80 days after infection.
Next, groups of mice (n=7) were dosed with 2 mg/kg/d
cordycepin and 0.2 mg/kg/d deoxycoformycin during 3, 5 or 7
days starting 20 days after infection. Again, a dose-dependent
trypanocidal effect was observed also in this experiment. Five or
three doses were not enough to completely clear infection, whereas
in the group treated with 7 doses only one animal remained
infected (Figure 2B). Since, a total of 2 of out of 25 mice in the
different experiments treated with 2 mg/kg/d cordycepin and
0.2 mg/kg/d deoxycoformycin for 7 days remained infected after
treatment, we concluded that this treatment is on the brink of the
minimal effective dose for clearance. We then increased the
number of doses used for treatment. When mice (8 per group)
were treated for 10 or 15 days with 2 mg/kg/d cordycepin and
0.2 mg/kg/d deoxycoformycin starting at day 20 after infection, a
complete curative effect was achieved in two independent
experiments (33 mice together) (Figure 2B and data not shown).
The minimal effective concentration of deoxycoformycin re-
quired for treatment was subsequently evaluated. For this purpose,
mice (8 per group) were treated for 10 days with 2 mg/kg/d
cordycepin and different concentrations of deoxycofomycin starting
20 days after infection with 2610
3 T.b. brucei. Treatment with either
0.1 or 0.2 mg/kg/d deoxycoformycin resulted in complete cure of
second stage infection, while no curative effect was observed when
0.02 mg/kg/ddeoxycoformycinwasusedfortreatment(Figure2C).
We also tested whether EHNA, another ADA inhibitor, could
replace deoxycoformycin in treatment of late stage infections.
Similar transient decreases in parasites levels in the blood were
observed when 2 mg/kg/d cordycepin was inoculated in presence
orabsenceof 0.2 mg/kg/dEHNA (data not shown),suggesting that
EHNA did not protect cordycepin from degradation.
Starting treatment with cordycepin and deoxycoformycin at 20
days after infection resulted in loss of weight of infected mice.
Surprisingly, toxicity was largely independent of the dose of
cordycepin and deoxycoformycin used, since mice treated either
for 15, 10, 7, 5 or 3 days with 2 mg/kg/d cordycepin and 0.2 mg/
kg/d deoxycoformycin or treated with 7 doses of 2, 1.2 or 0.6 mg/
kg/d cordycepin and 0.2 mg/kg/d deoxycoformycin all showed
similar weight loss (Figure 2D, E and data not shown). All mice
recovered weight after the treatment. No other sign of morbidity
was noted. Importantly, weight loss was not observed in uninfected
mice treated with 2 mg/kg/d cordycepin and 0.2 mg/kg/d
deoxycoformycin (data not shown). Thus, the treatment toxicity
required simultaneous presence of an established infection.
Figure 2. Minimal effective doses of cordycepin and deoxycoformycin for treatment of late stage infection with T.b. brucei. A, D
Different concentrations of cordycepin with a 0.2 mg/kg/d deoxycoformycin were inoculated i.p. for 7 days into mice starting 20 days after infection
with 2610
3 T.b. brucei. B, E Different number of doses of 2 mg/kg cordycepin and 0.2 mg/kg/d deoxycoformycin were inoculated starting 20 days
after infection with 2610
3 T. brucei. C, F Different doses of deoxycoformycin were inoculated i.p. daily for 10 days with 2 mg/kg cordycepin starting
20 days after infection with T. brucei. A–C The fraction of mice with detectable parasitemia is depicted. D–F The mean of weight change in relation to
that before infection in each group6standard error the mean is shown.
doi:10.1371/journal.pntd.0000495.g002
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method to evaluate parasite dissemination in vivo. BALB/c mice
were infected with 2610
3 luciferase-tagged T.b. brucei AnTat1.1.
Bioluminescent images showed a systemic spread of infection. No
light emission was observed from mice treated with the doublet
during late stage of infection (Figure 3), confirming the efficiency
of treatment with cordycepin and deoxycoformycin.
Oral and subcutaneous administration of cordycepin and
deoxycoformycin
The customary i.v. administration of trypanocidal drugs requires
trained medical personnel, and specialized equipment and
materials. Oral administration of these compounds would facilitate
their use in patients. The effect of oral administration of cordycepin
and deoxycoformycin in the outcome of murine infection with T. b.
Figure 3. Dynamics of infection with T.b. brucei AnTat 1.1 infection in mice treated or not with cordycepin and deoxycoformycin,
visualized by bioluminescence imaging. Parasite load in BALB/c male mice injected i.p. with 2610
4 luciferase recombinant T.b. brucei AnTat 1.1
was assessed daily by biophotonic emission determination as indicated in material and methods. Parasitemia levels were registered in parallel.
doi:10.1371/journal.pntd.0000495.g003
Figure 4. Curative effect of oral and subcutaneous inoculation of cordycepin and deoxycoformycin on early and late stage
infection with T.b. brucei. A Mice were orally administered with the indicated doses of cordycepin with 0.2 mg/kg/d deoxycoformycin in presence
or absence of omeprazole, daily 3 times starting at the day of infection with 2610
3 T.b. brucei. B Mice were orally administered with the indicated
doses of cordycepin with deoxycoformycin in presence of omeprazole, daily 10 times starting at the day 20 after infection with 2610
3 T.b. brucei.C
Mice were inoculated s.c. daily for 10 days with 2 mg/kg cordycepin and 0.2 mg/kg deoxycoformycin in vegetable oil or with oil alone. The fraction of
mice with detectable parasitemia is indicated in A, B and C.
doi:10.1371/journal.pntd.0000495.g004
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15 mg/kg/d cordycepin with 0.2 mg/kg/d deoxycoformycin
cured approximately 50% of the treated mice when treatment
was started at the day of infection and continued for 3 days. While
oral administration of cordycepin has been shown to be an effective
anti-tumoral agent [25], deoxycoformycin has a well described
acid-lability that has hampered its use in oral formulations.
Cordycepin and deoxycoformycin were then administered with
omeprazole, a proton pump inhibitor, to reduce acid concentration
in the stomach and thereby allow absorption of enhanced
concentrations of the ADA inhibitor. Daily treatment of mice at
the day of infection with cordycepin plus deoxycoformycin in
presence of omeprazole for 5 days resulted in cure of the infection
of all (n=6) treated mice (Figure 4A). We then tested if oral
administration of the doublet was effective for treatment of second
stage infection with T. b. brucei. We found that oral administration
of 15 mg/kg/d cordycepin and 0.4 mg/kg/d deoxycoformycin,
but not 5 mg/kg/d cordycepin and 0.2 mg/kg/d deoxycoformy-
cin, for 10 days starting 20 days after infection had a complete
curative effect (Figure 4 B).
Subcutaneous treatment with 2 mg/kg/d and 0.2 mg/kg/d
deoxycoformycin diluted in 100 ml of vegetable oil daily for 10
days starting on day 20 after infection with T.b. brucei was also
effective in curing late stage infection of treated animals.
Administration of 4 mg/kg/d cordycepin and 0.2 mg/kg/d
deoxycoformycin s.c. every other day failed to cure all treated
mice, suggesting that strategies improving pharmacokinetics of the
doublet might improve treatment efficiency (Figure 4C).
Cordycepin and deoxycoformycin treatment of infections
with human pathogenic T. brucei isolates
We then studied whether late stage infection with human
pathogenic strains of T. brucei can be treated with cordycepin and
deoxycofomycin. Two weeks after infection with 10
4 T.b. rhodesiense
STIB 851 isolate, parasites were detected in the brain parenchy-
ma. Parasite density in the brain parenchyma increased at later
times of infection (Figure 5A, B). Parasitemia levels were low or
undetectable compared to T.b. brucei AnTat1.1 (Figure 5 C), but
mice lost weight and showed signs of morbidity at 35–40 days after
infection (data not shown). Ten days of dosing of 2 mg/kg/d
Figure 5. Curative treatment with cordycepin and deoxycoformycin on late stage experimental T.b. rhodesiense infection. Mice were
inoculated i.p. with 2610
4 T.b. rhodesiense. Increasing density of parasite immunostaining in the brain parenchyma was observed at 15, 21 and 28
days after infection (data not shown). A representative section of parasite immunostaining in the brain of mice at day 21 after infection is shown in A.
Note in green labeling of brain endothelial cells and in red, T. brucei. An uninfected mouse brain section incubated with both antibodies is shown as a
negative control in panel B. C Groups of mice were infected with T.b. rhodesiense and inoculated i.p. daily for 10 days with 2 mg/kg/d cordycepin and
0.2 mg/kg/d deoxycoformycin starting 21 days after infection, or left untreated. The mean log parasitemia of cordycepin and deoxycoformycin
treated T.b. rhodesiense infected mice is indicated. D The mean log parasitemia from groups (n=7 animals per group) infected with 2610
5 T.b.
gambiense and treated with cordycepin and deoxycoformycin for 10 days starting 30 days after infection, or left untreated is depicted.
doi:10.1371/journal.pntd.0000495.g005
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infection in mice as evaluated by real time PCR and inoculation of
lysates of brains from mice 65 days after treatment to naı ¨ve
immunodeficient mice (data not shown).
The effect of cordycepin and deoxycoformycin administration
on the outcome of infection with T.b. gambiense was then evaluated.
T.b.gambiense isolates were also susceptible to cordycepin in vitro
(data not shown). Whereas mice inoculated i.p. with 2610
5 T.b.
gambiense (MBA stabilates) showed parasitemia up to at least 70
days after infection, mice inoculated 2610
3 or 2610
4 T.b. gambiense
showed no parasites in the blood. In contrast to T.b. rhodesiense,
morbidity was only observed in T.b. gambiense-infected mice at the
time of sacrifice (80 days after infection) with small numbers of
parasites observed in brain parenchyma, with elevated parasite
densities observed only in the septum (data not shown). Treatment
of T.b. gambiense infected mice with 2 mg/kg/d cordycepin and
0.2 mg/kg/d deoxycoformycin for 10 days, starting at 30 days
after infection, when parasites where first detected in the brain
parenchyma, completely eliminated parasitemia for at least 50
days after treatment (Figure 5 D).
Thus, treatment with cordycepin and deoxycoformycin was
effective in treatment of late stage infection with both human
pathogenic subspecies.
Cordycepin and deoxycoformycin treatment diminished
accumulation of pro-inflammatory cytokines in the brain
Brains from T.b. rhodesiense-infected mice treated with cordyce-
pin and deoxycoformycin starting 20 days after infection
contained diminished levels of IFN-c, IL-1b, IL-6 and TNF-a
mRNA compared to untreated infected controls when measured
10 days after treatment (Figure 6A–D). Likewise, brains from mice
infected with T.b. rhodesiense and treated with cordycepin and
deoxycoformycin starting 20 days after infection with T.b rhodesiense
contained lower levels of pro-inflammatory cytokine transcripts
when studied after 80 days after infection, as compared to non-
treated infected groups. Cytokine mRNA levels in infected and
cordycepin and deoxycoformycin-treated mice and in uninfected
mice were similar. (Figure 6E–H).
Cordycepin-induced programmed cell death of parasites
The mechanisms accounting for the trypanocidal effect of
cordycepin were subsequently explored. Several trypanocidal drugs
have been shown to activate a programmed cell death of T. brucei
[26]. We found that incubation with 1 mM cordycepin induced
degradation of DNA by measured by propidium iodide (PI) staining
of permeabilized parasites. DNA degradation was detected 1 h after
cordycepin treatment and it increased with time (Figure 7A). DNA
fragments were also detected by the TUNEL assay in cordycepin-
treated parasites (Figure 7C). One of the earliest indications of
apoptosisisthetranslocationofphosphatidylserinefromtheinnerto
the outer leaflet of the plasma membrane. Parasites treated with
1 mM cordycepin showed translocation of phosphatidylserine as
indicated bythe bindingof annexin V asearly as1 h after treatment
(Figure 7B). On the other hand, no alterations in mitochondrial
redox potential of cordycepin-treated parasites were detected
(Figure S1; Text S1). DNA degradation occurred in the absence
Figure 6. Levels of pro-inflammatory cytokine transcripts in brains of T.b. rhodesiense and T.b. gambiense-infected, cordycepin and
deoxycoformycin-treated mice. Total RNA was extracted from brain tissues of mice 30 days after inoculation with T.b. rhodesiense A–D) or 80 days
after inoculation with T.b. gambiense E–H), treated or not with 2 mg/kg/d cordycepin and 0.2 mg/kg/d deoxycoformycin starting 20 or 30 days after
infection respectively, converted into cDNA and pro-inflammatory mRNA accumulation was measured by real time PCR. The number of moles of
cytokine per mole of HPRT in samples from individual mice (4–6 per group) was calculated and the fold increase of IL-1 A, E), IL-6 B, F), IFN2c C, G),
TNF-a D, H) in cordycepin and deoxycoformycin treated or untreated infected mice with respect to levels in brains of one of the uninfected mice
depicted. *Differences with untreated, infected group are significant (p,0.05 Student t test).
doi:10.1371/journal.pntd.0000495.g006
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cordycepin treatment (Figure 7D), indicating that cordycepin
induced programmed cell death of T.b. brucei which was followed
by a secondary necrosis.
Cordycepin-induced drug resistance
Whether T. b. brucei can develop resistance against cordycepin
was then studied. For this purpose T. b. brucei AnTat1.1 and Lister
427 were incubated with low concentrations (1 LD50 or higher
doses) of cordycepin for 72 h at 37uC. Parasites surviving the
highest concentrations of cordycepin, were then further cultured
for 3 days with similar or higher concentrations of cordycepin.
This procedure was repeated for four months, after which a 40–60
fold increased resistance to cordycepin, compared to the parental
strain was achieved (Figure 8A, F).
Resistance to the nucleoside analogue was retained after culture
of the resistant parasites for three weeks in absence of cordycepin,
suggesting that resistance was due to genetic alterations rather
than to a metabolic adaptation of the parasite (Figure 8 B, G).
Cordycepin-resistant parasites were then incubated with melarso-
prol, pentamidine and suramine to determine cross-resistance. No
cross-resistance with these trypanocidal drugs was observed,
indicating that these trypanocidal compounds have non-overlap-
ping molecular targets (Figure 8C–E, H–J).
Figure 7. Cordycepin induces programmed cell death of trypanosomes. T.b. brucei were treated for the indicated times with 1 mM
cordycepin and staining with annexin V, propidium iodide (PI), and Tunel (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling)
was evaluated by FACS analysis. A T.b. brucei were incubated for the indicated time with 1 mM cordycepin, fixed with digitonin and stained with PI.
Note presence of subG1 peaks indicative of DNA fragmentation at 1 h after treatment and extensive DNA degradation at 3 h after incubation with
cordycepin. B T.b. brucei were incubated with 1 mM cordycepin, incubated at 37uC and stained with Annexin V at the indicated time points. C DNA
fragmentation in individual fixed T.b. brucei before and after incubation with 1 mM cordycepin was visualized by detection of biotinylated nucleotides
incorporated onto the free 39–hydroxyl residues of DNA fragments. Biotinylated nucleotides were then stained with streptavidin-FITC. As a positive
control, T.b. brucei were fixed, treated with DNAse I and the fragmented DNA was labeled biotinylated nucleotides. Negative controls included
cordycepin untreated labeled and unlabeled parasites. D To study necrosis after treatment of T.b. brucei with 1 mM cordycepin, nuclei were stained
with propidium iodide (5 mg/ml) in the absence of a cell permeant and analyzed by FACS.
doi:10.1371/journal.pntd.0000495.g007
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compared to their respective parental strains (Figure 9A, B). In vivo,
mice inoculated with cordycepin-resistant parasites showed delayed
and lower parasitemia levels compared to controls (Figure 9C, D).
Parasitemia in mice inoculated with cordycepin-resistant AnTat1.1
became undetectable. Loss of weight was registered in mice infected
with the parental strains but this effect was reduced in mice infected
with cordycepin resistant strains (data not shown).
Sequence analysis of candidate target genes
In order to determine possible cordycepin targets we amplified,
cloned and sequenced 11 candidate genes involved in uptake and
salvage of adenosine analogues in resistance-induced and parental
parasites. The TbAT1, TbNT2, TbNT4, TbNT6, TbNT12
nucleoside transporter genes, TbHT1 hexose transporter, TbAK
adenosine kinase, TbHGPRT hypoxanthine-guanine phosphoribo-
syltransferase from parental and resistant strains were screened for
mutations that could causean affected or deleterious protein function.
The HT1 was selected since this hexose transporter can be
inhibited by tubericidin [24]. TbNT2 is predominantly expressed
when compared to other genes in P1 family. The expression of
TbNT3, TbNT4, TbNT5, TbNT7, is not seen in a parental T. b.
brucei strtain. It has been reported that loss of primary transporter
P2 leads to over expression of TbNT4 and TbNT6 [27]. TbNT2,
4, 6 and 12 were therefore selected for sequencing.
While several polymorphisms were found, no deleterious
mutations were found in the genes sequenced except for TbAT1.
TbAT1 is a nucleoside adenosine transporter present in the
genome of T. brucei as a 1392 bp single copy gene where both
alleles have been found to be almost identical. We found two
mutations in the cordycepin-resistant AnTat1.1 strain TbAT1
gene that were not present in the respective parental DNA. There
was a single base insertion at position 61 and a single base deletion
at position 631, that could cause synthesis of a non-functional
truncated gene product were found (Figure 10B). Five out of 12
sequenced colonies presented the one base insertion while the
other seven carried the deletion, both groups with a read coverage
of 156, which confirmed the mutations. We assume that these two
sequences detected correspond to the two alleles of TbAT1
carrying different mutations but rendering the same non-
functional transporter protein.
For the cordycepin-resistant monomorphic Lister 427 strain,
PCR using primers designed at the 59 and 39 ends of the gene and
at the 59 and 39 UTRs were unable to amplify any product
(Figure 10A), while the same set of primers amplified the TbAT1
gene from the parental DNA. We assume that in this case the
Figure 8. Cordycepin-resistance strains are not cross resistant to suramin, pentamidine and melarsoprol. Cordycepin-resistant
pleomorphic AnTat1.1 A–E) and monomorphic Lister 427 F–J) parasites were induced after selection with increasingly higher concentrations of the
cordycepin during four months of culture. Parasites in all sub-panels were incubated with the indicated molar concentrations of the trypanocidal
compounds for 70 h, when WST-1 reagent added. Two h after incubation, parasite viability was measured. The fraction of parasites in comparison to
untreated controls is depicted. A, F Four months after incubation with cordycepin, parasites reached a 40–60 fold decreased sensitivity to cordycepin.
B, G Resistance to different concentrations cordycepin after 4 week-long culture of resistant parasites in absence of the drug is shown. Sensitivity of
cordycepin-resistant pleomorphic parasites to melarsoprol C, H), pentamidine D, I) or suramin E, J) is depicted.
doi:10.1371/journal.pntd.0000495.g008
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or the complete gene sequence, as amplification with internal
primers although producing a PCR fragment, was not of the
expected size (data not shown).
Since cordycepin resistant monomorphic (Lister 427) and
pleomorphic(AnTat1.1)parasitesdisplayedmutationsintheTbAT1
gene, we tested whether this transporter affected the susceptibility of
parasites to cordycepin by using TbAT1 knockout parasites. We
found that resistance of cordycepin by knockout parasites was only
slightly affected by the mutation, suggesting that the absence of the
P2 transporter is not sufficient to explain the observed increased
resistance of parasites to cordycepin (Figure 10C).
Discussion
We here report a preclinical evaluation of the chemotherapeutic
efficiency of cordycepin and deoxycoformycin for late stage
infection with T. brucei. In brief, cordycepin was selected from a
direct parasite viability screening of a compound library of
nucleoside analogues. The minimal effective concentrations of
cordycepin and deoxycoformycin for late stage treatment in vivo
were determined. Of importance, the dose of deoxycoformycin
used is similar or lower to that employed in leukemia patients, and
cordycepin and deoxyformycin have been tested in clinical trials in
humans (R McCaffrey, Harvard Medical School, Boston, personal
communication) and in preclinical studies in dogs at higher
concentrations to the ones here presented [28]. The compounds
could be given i.p., s.c. and orally, and our data suggests that a
slow release of the compounds in vivo will improve efficacy of
treatment by reducing the doses, and that enteric coating might
reduce the problem of acid lability of deoxycoformycin. The
nucleoside analogue treatment was also effective for treatment of
late stage infections with both T.b. rhodesiense and T.b. gambiense,
different to some drugs in clinical use such as DFMO
Figure 9. Cordycepin-resistant parasites showed diminished growth in vitro and diminished virulence in vivo. A, B The growth of
resistant-induced or parental parasites were measured by WST-1 oxidation at different time points after incubation of similar numbers of resistance-
induced and the parental monomorphic A) or pleomorphic B) parasites. The doubling times for the monomorphic parental population was 5.6 h and
14.6 h for the resistant strain. The doubling time for the pleomorphic strain was 27 h and 45 h for the cordycepin-resistant parasites. C, D Parasitemia
of mice inoculated i.p. with 2610
4 resistant-induced or parental T.b. brucei monomorphic C) or pleomorphic D) strains. The insert to figure D shows
that despite lower level of parasitemia in comparison to parental strains, parasitemia can be registered in a fraction of mice infected with the
pleomorphic cordycepin-resistant strain.
doi:10.1371/journal.pntd.0000495.g009
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Cordycepin and deoxycoformycin treatment diminished the
inflammatory cytokine accumulation in the brains of infected
mice. In agreement, the number of CD45+ inflammatory cells in
the brain parenchyma of T. brucei-infected mice was also reduced
after treatment cordycepin and deoxycoformycin [15]. We found
standard parameters associated to programmed cell death in T.
brucei to be similar to those described in pluricellular organisms.
Programmed cell death was followed by secondary necrosis.
Interestingly, programmed cell death processes have previously
been shown to be activated during the life cycle of trypanosoma-
tids, regulating parasite number in certain host tissues, in the
maintenance of clonality, as a mechanism of immunomodulation
and of parasite differentiation [29]. Cordycepin thus stimulates a
natural process of cell death, suggesting the presence of parasite
cordycepin-sensitive targets regulating such processes.
The development of this new drug combination with reduced
toxicity,highactivity and oralavailability gives riseto renewed hope
of new and safer treatments of HAT. However, the utility and
longevity of these new treatments will, to a large degree, be
determined by the development of parasite resistance to the drug.
We found that although T.b. brucei developed resistance to
cordycepin upon prolonged culture with low doses of the
compound, such resistant parasites showed diminished virulence
and reduced growth in vivo. Moreover, resistant parasites showed no
cross resistance to melarsoprol, suramin and pentamidine in clinical
use for early or late stage treatment of HAT, suggesting that
cordycepin targets aredifferent to those of the otherdrugs. Thisis of
importance since a strategy to delay or prevent the development of
resistance is to combine drugs that act on different targets and
therefore are unlikely to show cross-resistance. Additionally,
synergistic effects may arise from a combination of two drugs that
act differently. In such a situation, the concentrations of the
combination partners can be reduced compared with those used in
a mono-therapy, which leads to better safety.
Since resistance to cordycepin was slowly increased during the
four months-long culture of the parasites with the drug (data not
shown), it is likely that a number of mutations had accumulated
during the process. After cloning and sequencing 11 candidate
genes from cordycepin-induced resistant and parental strains, we
found that parasites showed altered functional mutations only in
the P2 transporter encoded by the TbAT1 gene. Although
mutations found in the other examined genes were present, they
did not show any predicted deleterious or altered effect for the
respective protein function. Cordycepin uptake has been reported
to be mediated by both the P1 and P2 transporters [27]. We found
however that a TbAT1 (P2) null parasite showed only slight
reduction in resistance to cordycepin, suggesting that other
undefined mutated genes also participate in increased sensitivity
to cordycepin of parental parasites.
Since cordycepin-resistant parasites show a genetic defect in
TbAT1, it was surprising that no cross resistance to pentamidine,
suramin and melarsoprol was not observed: the P2 transporter has
been shown to be responsible for uptake of different trypanocides
such as melaminyl arsenicals, pentamidine, diminazenes, cordy-
cepin and tubercidin [30,31,32,33]. Homozygously disrupted
TbAT1 null T. brucei showed two- and three-fold increases
resistance to melarsoprol and melarsen [17].
Figure 10. Sequencing of candidate genes. A) The PCR DNA amplification from T.b. brucei pleomorphic AnTat1.1 or monomorphic Lister 427
parasites is shown. Primers recognizing the 59 and 39 UTR and the 59 and 39 ends of the ORF of the TbAT1 gene were used. B) A single base insertion
at position 61 and a single base deletion at position 631, causing the synthesis of a non-functional truncated gene product in clones of the resistant
pleomorphic strain but not in the parental or in the genome annotated strain (Lister 427). C) TbAT1
2/2 and parental parasites were incubated with
different doses of cordycepin for 70 h, when WST-1 reagent added. Two h after incubation, parasite viability was measured. The fraction of parasites
in comparison to untreated controls is depicted.
doi:10.1371/journal.pntd.0000495.g010
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half of the twentieth century, and some of them would not pass
current high safety standards. A safe drug that is effective in the
treatment of the encephalitic stage of HAT would significantly
change the control and management of sleeping sickness. The data
here presented strongly suggest that the combination of cordyce-
pin and deoxycoformycin can be used in clinical tests for treatment
of African trypanosomiasis. Besides the results from the preclinical
experiments described in our manuscript, cordycepin fulfills a
number of requirements for to be considered a candidate drug: It
is available for other purposes and cheap, it can be given orally,
clinical trials of the doublet have been performed and toxicity in
man at the same concentrations used in animals seems not to pose
a problem.
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